Turner Investments’s Pacira BioSciences PCRX Stock Holding History

Turner Investments’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-8,000	Closed	-$614K	–	244
2015 Q4	$614K	Buy	+8,000	New	+$453K	0.13%	179
2015 Q1	–	Sell	-6,470	Closed	-$574K	–	500
2014 Q4	$574K	Sell	6,470 -48,880	-88%	-$4.62M	0.07%	329
2014 Q3	$5.37M	Buy	55,350 +8,270	+18%	+$805K	0.32%	90
2014 Q2	$4.33M	Buy	+47,080	New	+$3.58M	0.19%	156

Other funds holding PCRX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Turner Investments's PCRX Position: Q1 2016 in Review

Turner Investments sold out of Pacira BioSciences (PCRX) in Q1 2016, closing a stake of 8,000 shares — an estimated $614K sold.

Turner Investments first reported a position in PCRX in Q2 2014 and held it in 4 quarters. The position peaked at $5.37M in Q3 2014. 180 funds tracked by Wall St. Rank hold PCRX as of Q1 2016.

Turner Investments reported no remaining Pacira BioSciences position as of Q1 2016 after selling out during the quarter.
Turner Investments sold 8,000 Pacira BioSciences shares in Q1 2016, an estimated $614K.
Turner Investments first reported a position in Pacira BioSciences in Q2 2014 and held it in 4 quarters.
Turner Investments's Pacira BioSciences position peaked at $5.37M in Q3 2014.
180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2016.

Based on Turner Investments's 13F filing for Q1 2016, filed 13 May 2016.